Division of Gastroenterology and Hepatology, Institute for Medical Science, Department of Internal Medicine, Chonbuk National University Medical School and Hospital, Jeonju, Jeonbuk, South Korea.
BMC Cancer. 2011 Feb 19;11:78. doi: 10.1186/1471-2407-11-78.
The molecular mechanisms of CC (cholangiocarcinoma) oncogenesis and progression are poorly understood. This study aimed to determine the genome-wide expression of genes related to CC oncogenesis and sarcomatous transdifferentiation.
Genes that were differentially expressed between CC cell lines or tissues and cultured normal biliary epithelial (NBE) cells were identified using DNA microarray technology. Expressions were validated in human CC tissues and cells.
Using unsupervised hierarchical clustering analysis of the cell line and tissue samples, we identified a set of 342 commonly regulated (>2-fold change) genes. Of these, 53, including tumor-related genes, were upregulated, and 289, including tumor suppressor genes, were downregulated (<0.5 fold change). Expression of SPP1, EFNB2, E2F2, IRX3, PTTG1, PPARγ, KRT17, UCHL1, IGFBP7 and SPARC proteins was immunohistochemically verified in human and hamster CC tissues. Additional unsupervised hierarchical clustering analysis of sarcomatoid CC cells compared to three adenocarcinomatous CC cell lines revealed 292 differentially upregulated genes (>4-fold change), and 267 differentially downregulated genes (<0.25 fold change). The expression of 12 proteins was validated in the CC cell lines by immunoblot analysis and immunohistochemical staining. Of the proteins analyzed, we found upregulation of the expression of the epithelial-mesenchymal transition (EMT)-related proteins VIM and TWIST1, and restoration of the methylation-silenced proteins LDHB, BNIP3, UCHL1, and NPTX2 during sarcomatoid transdifferentiation of CC.
The deregulation of oncogenes, tumor suppressor genes, and methylation-related genes may be useful in identifying molecular targets for CC diagnosis and prognosis.
胆管癌(CC)发生和发展的分子机制尚不清楚。本研究旨在确定与 CC 发生和肉瘤样转化相关的基因的全基因组表达。
使用 DNA 微阵列技术鉴定 CC 细胞系或组织与培养的正常胆管上皮(NBE)细胞之间差异表达的基因。在人 CC 组织和细胞中验证表达。
通过对细胞系和组织样本的无监督层次聚类分析,我们确定了一组 342 个共同调节的(>2 倍变化)基因。其中,包括肿瘤相关基因在内的 53 个基因上调,包括肿瘤抑制基因在内的 289 个基因下调(<0.5 倍变化)。在人胆管癌和仓鼠胆管癌组织中,免疫组织化学验证了 SPP1、EFNB2、E2F2、IRX3、PTTG1、PPARγ、KRT17、UCHL1、IGFBP7 和 SPARC 蛋白的表达。与三种腺癌 CC 细胞系相比,肉瘤样 CC 细胞的额外无监督层次聚类分析显示 292 个差异上调基因(>4 倍变化),和 267 个差异下调基因(<0.25 倍变化)。免疫印迹分析和免疫组织化学染色验证了 12 种蛋白质在 CC 细胞系中的表达。在分析的蛋白质中,我们发现 EMT 相关蛋白 VIM 和 TWIST1 的表达上调,以及在 CC 的肉瘤样转化过程中,LDHB、BNIP3、UCHL1 和 NPTX2 等甲基化沉默蛋白的表达恢复。
癌基因、肿瘤抑制基因和甲基化相关基因的失调可能有助于识别 CC 诊断和预后的分子靶标。